Efficacy of levofloxacin and colistin inhalation form in treatment of pneumonia

Phase 1

Recruiting

• Conditions: Ventilator associated pneumonia (VAP) caused by multidrug resistant pathogens.; Ventilator associated pneumonia; J95.851

• Registration Number: IRCT20100107003014N26
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Age older than 18 years and less than 80 years
Mechanical ventilation for more than 48 hours
Pneumonia diagnosis based on the 2016 guidelines of the Infectious Diseases Society of America (IDSA)
CPIS score above 6
Positive culture of sputum sample and growth of gram-negative bacteria resistant to treatment (MDR) (Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, etc.)

Exclusion Criteria

Pregnancy or breastfeeding
History of allergy to any of the drugs Colistin, Levofloxacin and Meropenem
Acute respiratory distress syndrome
Pulmonary tuberculosis disease under treatment
Cystic fibrosis disease
Major interaction of other drugs used by the patient with levofloxacin, colistin or meropenem
Baseline creatinine clearance less than 15 mL/min
History of receiving antibiotics effective against MDR pathogens during hospitalization
Presence of pneumonia before intubation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Average CPIS score reduction in two groups. Timepoint: days 1, 5, 7 (or stop intervention day). Method of measurement: CPIS scoring table.